

PTO/SB/08B(10-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	10/763,815
Filing Date	January 22, 2004
First Named Inventor	Tette Van der Lende
Group Art Unit	1615
Examiner Name	C. Hagopian
Attorney Docket Number	2183-6293US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/C.H./		AHMED et al., Angiogenesis and intrauterine growth restriction, Bailliere's Clinical Obstetrics and Gynaecology, 2000, pp. 981-98, Vol. 14, No. 6.	
		BERISHA et al., Ovarian function in ruminants, Domestic Animal Endocrinology, 2005, pp. 305-17, Vol. 29.	
		GEVA et al., Role of vascular endothelial growth factor in ovarian physiology and pathology, Fertility and Sterility, September 2000, pp. 429-38, Vol. 74, No. 3.	
		MAYHEW et al., Morphometric Evidence that Villous Development and Fetoplacental Angiogenesis are Comprised by Intrauterine Growth Restriction but not by Pre-eclampsia, Placenta, 2004, pp. 829-33, Vol. 25.	
		MUROHARA et al., Nitric Oxide Synthase Modulates Angiogenesis in Response to Tissue Ischemia, J. Clin. Invest., pp. 2567-78, Vol. 101, No. 11.	
		REDMER et al, Effect of nutrient intake during pregnancy on fetal and placental growth and vascular development, Domestic Animal Endocrinology, 2004, pp. 199-217, Vol. 27.	
		REYNOLDS et al., Animal Models of Placental Angiogenesis, Placenta, 2005, pp. 689-708, Vol. 26.	
		WITZENBICHLER et al., Vascular Endothelial Growth Factor-C (VEGF-C/VEGF-2) Promotes Angiogenesis in the Setting of Tissue Ischemia, American Journal of Pathology, August 1998, pp. 381-94, Vol. 153, No. 2.	
		WU et al., Board-invited Review: Intrauterine growth retardation: Implications for the animal sciences; J. Anim. Sci, 2006, pp. 2316-37, Vol. 84.	
		ZIMMERMANN et al, Vascular endothelial growth factor receptor 2-mediated angiogenesis is essential for gonadotropin-dependent follicle development, The Journal of Clinical Investigation, September 2003, pp. 659-69, Vol. 112, No. 5.	
/C.H./		ZYGMUNT et al., Angiogenesis and vasculogenesis in pregnancy, European Journal of Obstetrics & Gynecology and Reproductive Biology, 2003, pp. S10-S18, Vol. 110.	

Examiner
Signature

/Casey Hagopian/

Date
Considered

03/03/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B(10-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/763,815
Filing Date	January 22, 2004
First Named Inventor	Tette Van der Lende
Group Art Unit	1615
Examiner Name	C. Hagopian
Attorney Docket Number	2183-6293UIS

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/C.H./		VAN DER LENDE et al., Effect of oral L-arginine supplementation of sows during two stages of pregnancy on litter size and birth weight, Final Trial Report of Project High Prolific Sow, November 2002, pp. 1-9.	
↓		RAMAEKERS et al., Abstract, Progenos in sows increases number of piglets born, J. Anim. Sci., 2006, p. 394, Vol. 84.	
↓		Nutrient Requirements of Swine, Tenth Revised Edition, 1998, National Academy of Sciences.	
↓		HAZELEGER et al., Influence of Nutritional Factors on Placental Growth and Piglet Imprinting, pp. 309-27.	
↓		HAZELEGER et al., Effects of Progenos on Placental and Fetal Development in Pigs, Abstract, Journal compilation, 2007, p. 135.	
↓		MALAMITSI-PUCHNER et al., Vascular endothelial growth factor and placenta growth factor in intrauterine growth-restricted fetuses and neonates. Mediators of Inflammation 2005, pp. 293-297, Vol. 5.	
↓		REGNAULT et al., The relationship between transplacental O2 diffusion and placental expression of PlGF, VEGF and their receptors in a placental insufficiency model of fetal growth restriction. Journal of Physiology, 2003, pp. 641-656, Vol. 550.	
↓		TAMANINI et al., Angiogenesis in developing follicle and corpus luteum. Reproduction in Domestic Animals, 2004, pp. 206-216, Vol. 39.	
/C.H./		WALLACE et al., Investigating the cause of low birth weight in contrasting ovine paradigms. Journal of Physiology, 2005, pp. 19-26, Vol. 565.	

Examiner
Signature

/Casey Hagopian/

Date
Considered

03/03/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.